단순 포진 각막염 치료 시장 : 제품 유형별, 최종사용자별, 지역별 - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)

Persistence Market Research has recently published an in-depth analysis of the global Herpes Simplex Keratitis Treatment Market, offering a comprehensive overview of key market dynamics, growth drivers, challenges, and emerging trends. This report provides valuable insights into the structure of the Herpes Simplex Keratitis Treatment Market, presenting exclusive data and statistics that forecast the market's growth trajectory from 2023 to 2030.

The market for treating global herpes simplex keratitis is projected to grow at a compound annual growth rate (CAGR) of 9%, reaching an estimated value of US$8.3 billion by the conclusion of 2030 from US$4.5 billion in 2023.

Key Insights:

• Herpes Simplex Keratitis Treatment Market Size (2023E): US$4.5 Bn
• Projected Market Value (2030F): US$8.3 Bn
• Global Market Growth Rate (CAGR 2023 to 2030): 9.0%
• Historical Market Growth Rate (CAGR 2018 to 2022): 7.9%

Herpes Simplex Keratitis Treatment Market- Report Scope:

Given the potential threat of blindness associated with herpes simplex keratitis, there's a growing urgency among patients and medical professionals for prompt treatment. This awareness drives increased demand for treatments that prioritize preserving vision and managing symptoms. Healthcare providers may emphasize such treatment plans, spurring innovation in the market. Efforts to educate patients about the risks of untreated keratitis could further boost treatment-seeking behavior. Increased funding and prioritization for research aimed at preventing blindness associated with the condition are also expected.

Market Growth Drivers:

Sophisticated diagnostic techniques enable early identification of herpes simplex keratitis, leading to quicker management and improved outcomes. Modern technology distinguishes between HSV-1 and HSV-2, guiding tailored treatment plans and increasing diagnostic accuracy. Point-of-care testing facilitates rapid decision-making, while molecular diagnostic methods ensure precise identification of the virus. Advanced imaging tools aid in visualizing corneal changes, aiding in diagnosis and treatment planning. AI-driven diagnostics and automation streamline processes, reducing errors. Comprehensive eye exams and telemedicine enhance accessibility to care, especially in underserved areas. Diagnostic instruments track therapy response, allowing for timely adjustments.

Market Restraints:

Market restraints for herpes simplex keratitis treatment encompass both financial and therapeutic challenges. The high costs associated with medications often render them unaffordable for many individuals, particularly in socioeconomically disadvantaged areas. This financial strain can lead to poor patient compliance and strain healthcare systems, potentially resulting in changes to coverage and reimbursement guidelines that further limit access to necessary prescription drugs. Additionally, the lack of highly specific antiviral therapies poses a significant obstacle. Without targeted medications, treatment options are limited, potentially leading to longer symptom durations, increased risk of complications, and the development of antiviral resistance. These challenges highlight the need for affordable treatment options and the development of more precise antiviral therapies to effectively manage herpes simplex keratitis.

Market Opportunities:

The rapid expansion of telemedicine and remote patient monitoring presents significant opportunities for improving the management of herpes simplex keratitis. Telemedicine enables patients to access specialized eye care services remotely, particularly in underserved areas, reducing the need for extensive travel. Remote consultations promote early diagnosis and treatment, facilitating prompt intervention. Additionally, remote patient monitoring allows healthcare providers to monitor treatment progress and make timely adjustments, optimizing care without frequent in-person visits. This approach not only alleviates the burden on patients and healthcare systems but also reduces the risk of virus transmission, particularly in public health emergencies. Integration of telemedicine with advanced diagnostic technologies enhances patient education, compliance, and remote evaluation of ocular issues associated with herpes simplex keratitis.

Key Questions Answered in the Report:

• What are the key factors driving the growth of the Herpes Simplex Keratitis Treatment Market?
• Which industry verticals are driving the demand for Herpes Simplex Keratitis Treatment?
• How are technological advancements reshaping the competitive landscape of the Herpes Simplex Keratitis Treatment Market?
• Who are the leading players in the global Herpes Simplex Keratitis Treatment Market?
• What are the emerging trends and future prospects in the global Herpes Simplex Keratitis Treatment Market?

Competitive Intelligence and Business Strategy:

Bausch Health focuses on maintaining its leading position in the herpes simplex keratitis (HSK) sector by continuously improving production, marketing, and distribution of its flagship product Zirgan. They also prioritize research and development for novel HSK therapies, including gene therapy and innovative drug delivery methods, to sustain a competitive product pipeline. Additionally, Bausch Health emphasizes enhancing the patient experience through education programs, support services, and user-friendly medication delivery systems to attract new clients and foster brand loyalty.

Cipla specializes in providing affordable generic versions of antiviral drugs for HSK treatment, catering primarily to patients in developing nations. Leveraging its extensive presence in over 80 countries, Cipla aims to reach underserved areas by collaborating with governments, nonprofits, and healthcare partners. These collaborations involve initiatives such as awareness campaigns, discounted prescription drugs, and strengthening healthcare systems to improve access to HSK treatment options.

Key Companies Profiled:

• GlaxoSmithKline
• Vectans Pharma
• Blistex
• Bausch Health
• Aurobindo Pharma
• Dr. Reddy's Laboratories
• Cipla
• Jubilant Cadista
• Mylan
• Novartis International AG

Herpes Simplex Keratitis Treatment Market Segmentation:

By Drug:

• Famciclovir
• Valacyclovir
• Acyclovir
• Other Drugs

By Route of Administration:

• Topical
• Injection
• Oral

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Herpes Simplex Keratitis Treatment Market Snapshot, 2023 and 2030
• 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Drug Lifecycle Analysis
• 2.4. Herpes Simplex Keratitis Treatment Market: Value Chain
  • 2.4.1. List of Raw Material Supplier
  • 2.4.2. List of Manufacturers
  • 2.4.3. List of Distributors
  • 2.4.4. List of Applications
  • 2.4.5. Profitability Analysis
• 2.5. Porter Five Force's Analysis
• 2.6. Geopolitical Tensions: Market Impact
• 2.7. Macro-Economic Factors
  • 2.7.1. Global Sectorial Outlook
  • 2.7.2. Global GDP Growth Outlook
  • 2.7.3. Global Parent Market Overview
• 2.8. Forecast Factors - Relevance and Impact
• 2.9. Regulatory and Route of Administration Landscape

3. Global Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 3.1. Key Highlights
  • 3.1.1. Market Volume (Units) Projections
  • 3.1.2. Market Size and Y-o-Y Growth
  • 3.1.3. Absolute $ Opportunity
• 3.2. Market Size (US$ Mn) Analysis and Forecast
  • 3.2.1. Historical Market Size Analysis, 2013-2016
  • 3.2.2. Current Market Size Forecast, 2018-2026
• 3.3. Global Herpes Simplex Keratitis Treatment Market Outlook: Drug
  • 3.3.1. Introduction / Key Findings
  • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug, 2018 - 2022
  • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
    • 3.3.3.1. Famciclovir
    • 3.3.3.2. Valacyclovir
    • 3.3.3.3. Acyclovir
    • 3.3.3.4. Other Drugs
• 3.4. Market Attractiveness Analysis: Drug
• 3.5. Global Herpes Simplex Keratitis Treatment Market Outlook: Route of Administration
  • 3.5.1. Introduction / Key Findings
  • 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Route of Administration, 2018 - 2022
  • 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
    • 3.5.3.1. Topical
    • 3.5.3.2. Injection
    • 3.5.3.3. Oral
• 3.6. Market Attractiveness Analysis: Route of Administration

4. Global Herpes Simplex Keratitis Treatment Market Outlook: Region

• 4.1. Key Highlights
• 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
• 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
  • 4.3.1. North America
  • 4.3.2. Europe
  • 4.3.3. East Asia
  • 4.3.4. South Asia and Oceania
  • 4.3.5. Latin America
  • 4.3.6. Middle East & Africa (MEA)
• 4.4. Market Attractiveness Analysis: Region

5. North America Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 5.1. Key Highlights
• 5.2. Pricing Analysis
• 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 5.3.1. By Country
  • 5.3.2. By Drug
  • 5.3.3. By Route of Administration
• 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 5.4.1. U.S.
  • 5.4.2. Canada
• 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
  • 5.5.1. Famciclovir
  • 5.5.2. Valacyclovir
  • 5.5.3. Acyclovir
  • 5.5.4. Other Drugs
• 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
  • 5.6.1. Topical
  • 5.6.2. Injection
  • 5.6.3. Oral
• 5.7. Market Attractiveness Analysis

6. Europe Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 6.3.1. By Country
  • 6.3.2. By Drug
  • 6.3.3. By Route of Administration
• 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 6.4.1. Germany
  • 6.4.2. France
  • 6.4.3. U.K.
  • 6.4.4. Italy
  • 6.4.5. Spain
  • 6.4.6. Russia
  • 6.4.7. Turkiye
  • 6.4.8. Rest of Europe
• 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
  • 6.5.1. Famciclovir
  • 6.5.2. Valacyclovir
  • 6.5.3. Acyclovir
  • 6.5.4. Other Drugs
• 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
  • 6.6.1. Topical
  • 6.6.2. Injection
  • 6.6.3. Oral
• 6.7. Market Attractiveness Analysis

7. East Asia Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 7.3.1. By Country
  • 7.3.2. By Drug
  • 7.3.3. By Route of Administration
• 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. South Korea
• 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
  • 7.5.1. Famciclovir
  • 7.5.2. Valacyclovir
  • 7.5.3. Acyclovir
  • 7.5.4. Other Drugs
• 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
  • 7.6.1. Topical
  • 7.6.2. Injection
  • 7.6.3. Oral
• 7.7. Market Attractiveness Analysis

8. South Asia & Oceania Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 8.3.1. By Country
  • 8.3.2. By Drug
  • 8.3.3. By Route of Administration
• 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 8.4.1. India
  • 8.4.2. Southeast Asia
  • 8.4.3. ANZ
  • 8.4.4. Rest of South Asia & Oceania
• 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
  • 8.5.1. Famciclovir
  • 8.5.2. Valacyclovir
  • 8.5.3. Acyclovir
  • 8.5.4. Other Drugs
• 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
  • 8.6.1. Topical
  • 8.6.2. Injection
  • 8.6.3. Oral
• 8.7. Market Attractiveness Analysis

9. Latin America Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 9.3.1. By Country
  • 9.3.2. By Drug
  • 9.3.3. By Route of Administration
• 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America
• 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
  • 9.5.1. Famciclovir
  • 9.5.2. Valacyclovir
  • 9.5.3. Acyclovir
  • 9.5.4. Other Drugs
• 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
  • 9.6.1. Topical
  • 9.6.2. Injection
  • 9.6.3. Oral
• 9.7. Market Attractiveness Analysis

10. Middle East & Africa Herpes Simplex Keratitis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 10.3.1. By Country
  • 10.3.2. By Drug
  • 10.3.3. By Route of Administration
• 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 10.4.1. GCC
  • 10.4.2. Egypt
  • 10.4.3. South Africa
  • 10.4.4. Northern Africa
  • 10.4.5. Rest of Middle East & Africa
• 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
  • 10.5.1. Famciclovir
  • 10.5.2. Valacyclovir
  • 10.5.3. Acyclovir
  • 10.5.4. Other Drugs
• 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
  • 10.6.1. Topical
  • 10.6.2. Injection
  • 10.6.3. Oral
• 10.7. Market Attractiveness Analysis

11. Competition Landscape

• 11.1. Market Share Analysis, 2022
• 11.2. Market Structure
  • 11.2.1. Competition Intensity Mapping By Market
  • 11.2.2. Competition Injection
  • 11.2.3. Apparent Product Capacity
• 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 11.3.1. GlaxoSmithKline
    • 11.3.1.1. Overview
    • 11.3.1.2. Segments and Product
    • 11.3.1.3. Key Financials
    • 11.3.1.4. Market Developments
    • 11.3.1.5. Market Strategy
  • 11.3.2. Vectans Pharma
    • 11.3.2.1. Overview
    • 11.3.2.2. Segments and Product
    • 11.3.2.3. Key Financials
    • 11.3.2.4. Market Developments
    • 11.3.2.5. Market Strategy
  • 11.3.3. Blistex
    • 11.3.3.1. Overview
    • 11.3.3.2. Segments and Product
    • 11.3.3.3. Key Financials
    • 11.3.3.4. Market Developments
    • 11.3.3.5. Market Strategy
  • 11.3.4. Bausch Health
    • 11.3.4.1. Overview
    • 11.3.4.2. Segments and Product
    • 11.3.4.3. Key Financials
    • 11.3.4.4. Market Developments
    • 11.3.4.5. Market Strategy
  • 11.3.5. Aurobindo Pharma
    • 11.3.5.1. Overview
    • 11.3.5.2. Segments and Product
    • 11.3.5.3. Key Financials
    • 11.3.5.4. Market Developments
    • 11.3.5.5. Market Strategy
  • 11.3.6. Dr. Reddy's Laboratories
    • 11.3.6.1. Overview
    • 11.3.6.2. Segments and Product
    • 11.3.6.3. Key Financials
    • 11.3.6.4. Market Developments
    • 11.3.6.5. Market Strategy
  • 11.3.7. Cipla
    • 11.3.7.1. Overview
    • 11.3.7.2. Segments and Product
    • 11.3.7.3. Key Financials
    • 11.3.7.4. Market Developments
    • 11.3.7.5. Market Strategy
  • 11.3.8. Jubilant Cadista
    • 11.3.8.1. Overview
    • 11.3.8.2. Segments and Product
    • 11.3.8.3. Key Financials
    • 11.3.8.4. Market Developments
    • 11.3.8.5. Market Strategy
  • 11.3.9. Mylan
    • 11.3.9.1. Overview
    • 11.3.9.2. Segments and Product
    • 11.3.9.3. Key Financials
    • 11.3.9.4. Market Developments
    • 11.3.9.5. Market Strategy
  • 11.3.10. Novartis International AG
    • 11.3.10.1. Overview
    • 11.3.10.2. Segments and Product
    • 11.3.10.3. Key Financials
    • 11.3.10.4. Market Developments
    • 11.3.10.5. Market Strategy

12. Appendix

• 12.1. Research Methodology
• 12.2. Research Assumptions
• 12.3. Acronyms and Abbreviations